Inferior vena cava filters: Concept review and summary of current guidelines

Luca Visconti,Alessandro Celi,Laura Carrozzi,Camilla Tinelli,Laura Crocetti,Francesco Daviddi,Raffaele De Caterina,Rosalinda Madonna,Roberta Pancani
DOI: https://doi.org/10.1016/j.vph.2024.107375
IF: 5.738
2024-04-25
Vascular Pharmacology
Abstract:Anticoagulation is the first-line approach in the prevention and treatment of pulmonary embolism. In some instances, however, anticoagulation fails, or cannot be administered due to a high risk of bleeding. Inferior vena cava filters are metal alloy devices that mechanically trap emboli from the deep leg veins halting their transit to the pulmonary circulation, thus providing a mechanical alternative to anticoagulation in such conditions. The Greenfield filter was developed in 1973 and was later perfected to a model that could be inserted percutaneously. Since then, this model has been the reference standard. The current class I indication for this device includes absolute contraindication to anticoagulants in the presence of acute thromboembolism and recurrent thromboembolism despite adequate therapy. Additional indications have been more recently proposed, due to the development of removable filters and of progressively less invasive techniques. Although the use of inferior vena cava filters has solid theoretical advantages, clinical efficacy and adverse event profile are still unclear. This review analyzes the most important studies related to such devices, open issues, and current guideline recommendations.
pharmacology & pharmacy
What problem does this paper attempt to address?